Trial Profile
A phase II study investigating preoperative MPDL3280A in operable transitional cell carcinoma of the bladder
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary)
- Indications Bladder cancer; Carcinoma
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- Acronyms ABACUS
- 27 Jan 2024 Results of an exploratory biomarker analysis using different definitions of ctDNA response and assessing correlation with tissue response at time of cystectomy from this trial presented at the 2024 Genitourinary Cancers Symposium
- 24 Oct 2023 Results assessing the relationship between EFN/EPH expression and response to atezolizumab using data of patients from this study, presented at the 48th European Society for Medical Oncology Congress.
- 01 Aug 2022 Final results reporting two year data on disease-free and overall survival outcomes and a biomarker analysis assessing novel tissue-based biomarkers and circulating tumor DNA (ctDNA) published in the European Urology